Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

Wei-Chih Chen,1 Abraham S Kanate,2,3 Michael Craig,2,3 William P Petros,1,3 Lori A Hazlehurst1–3 1Department of Pharmaceutical Sciences, School of Pharmacy, 2Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, 3West Virginia University Cancer Institute, M...

Full description

Bibliographic Details
Main Authors:	Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-07-01
Series:	Cancer Management and Research
Subjects:	elotuzumab SLAMF7 relapsed/refractory multiple myeloma (RRMM)
Online Access:	https://www.dovepress.com/emerging-combination-therapies-for-the-management-of-multiple-myeloma--peer-reviewed-article-CMAR

Similar Items

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
by: Friend R, et al.
Published: (2017-03-01)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
by: Kerry S. Campbell, et al.
Published: (2018-11-01)

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
by: Tatiana Pazina, et al.
Published: (2017-09-01)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
by: Emily Chu, et al.
Published: (2023-08-01)

Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01)

Elotuzumab as a novel anti-myeloma immunotherapy
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017-08-01)

Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
by: Wilke T, et al.
Published: (2018-11-01)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
by: Klaus Podar, et al.
Published: (2021-10-01)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
by: Morgane Humbel, et al.
Published: (2021-03-01)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
by: Fortunato Morabito, et al.
Published: (2022-07-01)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
by: Joseph Kauer, et al.
Published: (2023-11-01)

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
by: Sundar Jagannath, et al.
Published: (2023-04-01)

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)
by: Hamid Ehsan, et al.
Published: (2024-03-01)

Rescue SLAMF7 activity in exhausted natural killer cells: Novel challenges in the immunotherapy of multiple myeloma
by: Alessandra Zingoni, et al.
Published: (2022-12-01)

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
by: Laura Gengenbach, et al.
Published: (2021-08-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Recent Advances in the Treatment of Patients with Multiple Myeloma
by: Mario A. Legarda, et al.
Published: (2020-11-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
by: Alessandra Romano, et al.
Published: (2021-07-01)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
by: Paola Storti, et al.
Published: (2020-09-01)

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
by: Tung-Lung Yang, et al.
Published: (2023-11-01)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
by: Tatiana Pazina, et al.
Published: (2021-01-01)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
by: Xiang Zhou, et al.
Published: (2020-07-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
by: Massimo Martino, et al.
Published: (2021-05-01)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
by: Xiang Zhou, et al.
Published: (2020-04-01)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
by: Javier de la Rubia, et al.
Published: (2023-05-01)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
by: Abubakar Tauseef, et al.
Published: (2022-01-01)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
by: Jiadai Xu, et al.
Published: (2022-01-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)